Blog & Haberler

PROs in Prostate Cancer: Patient-Reported Outcomes, Quality of Life, and the Turp Digital Platform

PROs in Prostate Cancer: Patient-Reported Outcomes, Quality of Life, and the Turp Digital Platform

Introduction: The Prostate Cancer and Quality of Life Paradox

Prostate cancer is one of the most common malignancies in men worldwide. Although objective prognostic factors such as Gleason score, PSA levels, and TNM staging indicate the biological behavior of the disease, they cannot fully reflect the functional losses, symptoms, and quality of life experienced by the patient during and after treatment.

Prostate cancer treatment (radical prostatectomy, radiotherapy, androgen deprivation therapy, chemotherapy) frequently causes quality-of-life issues in male patients, including erectile dysfunction (ED), urinary incontinence, and gastrointestinal side effects. These problems profoundly affect patients' quality of life, social relationships, and mental health.

It is precisely at this point that Patient-Reported Outcomes (PROs) have begun to play a critical role in prostate cancer research and clinical practice. PROs go beyond objective medical data, bringing the patient's own voice and real-life experience into research.

In this comprehensive guide, we will examine in detail the strategic importance of PROs in prostate cancer treatment, quality-of-life measurements, side-effect management, and the transformation the Turp platform brings to this field.


1. Prostate Cancer Treatment and the Inadequacy of Traditional Success Criteria

Traditional Treatment Outcome Measures

In prostate cancer research, the following objective parameters have long been used as indicators of success:

  • Recurrence-Free Survival (RFS)
  • Overall Survival (OS)
  • PSA Response Rate (50% or greater PSA decline)
  • Radiological Response (per RECIST criteria)

The Clinical Paradox: Good Objective Outcomes, Poor Quality of Life

Problem: Many prostate cancer patients, after receiving objectively "successful" treatment (disease in remission, PSA normalized), complain of the following issues:

  • Erectile Dysfunction (ED): After radical prostatectomy, permanent ED develops in 40-60% of cases; after radiotherapy, in 20-50%.
  • Urinary Incontinence: Persistent incontinence occurs in 5-20% of cases after surgery.
  • Gastrointestinal Side Effects: Diarrhea and anorectal problems can persist chronically after radiotherapy.
  • Androgen Deprivation Side Effects: Patients on ADT may experience weight gain, osteoporosis, fatigue, and cognitive decline.
  • Mental Health: Anxiety, depression, and social isolation are frequently observed.

The Gap in Traditional Approaches: Classical RCTs do not adequately measure or report these quality-of-life issues. Clinical outcomes may be limited to "remission" and "survival," while the patient's daily life may be significantly affected.


2. PROs: Quantitative Measurement of Patient Experience in Prostate Cancer

PROs in the Context of Prostate Cancer

A PRO (Patient-Reported Outcome) is the patient's own direct report of the symptoms, side effects, quality of life, and functional status they experience before, during, and after prostate cancer treatment. These measurements, made by the patient without any physician or nurse interpretation, demonstrate the true impact of treatment.

Prostate Cancer-Specific PRO Measures

1. Quality-of-Life Questionnaires

EORTC QLQ-C30 + PR25 Module

  • Measures general quality of life in cancer patients (EORTC QLQ-C30)
  • Measures prostate-specific side effects (PR25 module): ED, incontinence, gastrointestinal symptoms

FACT-P (Functional Assessment of Cancer Therapy - Prostate)

  • A quality-of-life questionnaire specifically designed for prostate cancer patients
  • Measures physical, social, emotional, and functional dimensions
  • Contains 39 questions and can be completed in a short time

SF-36 (Short Form 36)

  • Measures general health status and quality of life
  • Evaluates physical and mental components

2. Functional Failure Measures

Erectile Function Scale (IIEF - International Index of Erectile Function)

  • 15 questions measuring male sexual function and satisfaction
  • Determines the severity of ED after prostate cancer treatment
  • Evaluates the effectiveness of therapeutic interventions (PDE-5 inhibitors, intracavernosal injections)

Urinary Incontinence Scale (ICIQ-UI SF - Incontinence Severity Index)

  • Measures the severity of incontinence and its impact on quality of life
  • Evaluates patient-reported daily urine leakage volume and social effects

Gastrointestinal Symptom Scale (GI module within EORTC QLQ-C30)

  • Measures diarrhea, vomiting, and post-defecation problems
  • Monitors gastrointestinal toxicity after radiotherapy

3. Psychosocial Outcomes

Depression and Anxiety Scales (PHQ-9, GAD-7)

  • Monitors mental health after prostate cancer diagnosis and treatment
  • Acts as a prognostic factor (depressive patients show worse adaptation)

Body Image and Sexuality Scale (Body Image Scale)

  • Measures changes in body perception and effects on sexual identity after treatment

3. Why Are PROs Critical in Prostate Cancer Research?

Data That Influences Treatment Selection

In prostate cancer, there are usually multiple treatment options (surgery vs. radiotherapy vs. active surveillance vs. combination). Different treatments may be appropriate for two patients with the same disease stage. PRO data enables:

  • Individualized Decision-Making: A patient more tolerant of ED and incontinence may receive more aggressive treatment; sensitive patients may be offered conservative approaches.
  • Patient Preference-Based Medicine: Treatment planning aligned with the patient's quality-of-life priorities (returning to work, sexual life, social activities)

Proactive Management of Side Effects

With Traditional Follow-Up: The patient mentions side effects during a doctor visit every 3-6 months, but problems experienced in between may go unreported.

With PRO-Supported Approach: Patients are prompted via the Turp app 1-2 times per week about ED, incontinence, and energy levels. Early detection of problems and proactive intervention (e.g., initiation of PDE-5 inhibitors for ED) become possible.

Regulatory Acceptability

The FDA and EMA have in recent years begun to take PRO data very seriously in the approval of prostate cancer drugs. For example:

  • In the approval of Enzalutamide, FACT-P quality-of-life results were presented
  • In Abiraterone studies, quality-of-life outcomes were reported alongside PSA response
  • For new hormonal agents and chemotherapeutics, PRO data influences market access and reimbursement decisions

4. Prostate Cancer RWE and PROs: The Real-World Ineffectiveness Problem

The Paradox Encountered in Clinical Practice

In RCTs, the PSA response rate in prostate cancer patients receiving androgen deprivation therapy (ADT) can be 80-90%. However, in real-world practice:

  • Patients may not take the medication properly (skipping weekends, reducing pill count)
  • Treatment adherence may decrease due to side effects (weight gain, osteoporosis, ED)
  • Persistence may be insufficient due to social and economic constraints

RWE + PRO Solution: Real-world adherence and persistence problems can be detected through PRO data, and interventions can be planned.


5. Turp App for Prostate Cancer Patients: An Integrated Solution

Turp's Prostate Cancer-Specific Features

1. e-Nabiz Integration: Comorbidity and Medication Tracking

Most prostate cancer patients are elderly and have comorbidities (hypertension, diabetes, cardiovascular disease). Through e-Nabiz integration, Turp:

  • Automatic Comorbidity Profile Retrieval: Comorbid conditions such as diabetes, heart disease, and osteoporosis are automatically loaded into Turp.
  • Drug-Drug Interaction Analysis: Interactions among ADT, chemotherapeutics, and comorbidity medications are automatically checked.
  • Cardiovascular Risk Monitoring: For ED treatment (PDE-5 inhibitors), special alert and control mechanisms are activated in patients with cardiac risk.

2. Prostate-Specific PRO Questionnaires

Turp's built-in PRO library contains questionnaires specifically designed for prostate cancer patients:

Weekly Monitoring Questionnaires:

  • "Did you experience frequent urination problems this week?" (1-10 severity scale)
  • "How many times did you go to the bathroom at night?" (objective count)
  • "Did you experience incontinence and how much?" (pad count)
  • "Do you have complaints about sexual function?" (IIEF mini)
  • "How are your general energy and fatigue levels?" (0-10 scale)
  • "How is your mood (depression/anxiety)?" (PHQ-2)

Monthly Comprehensive Questionnaires:

  • Full FACT-P quality-of-life questionnaire
  • Full IIEF-15 male function questionnaire
  • ICIQ-UI SF incontinence questionnaire
  • SF-36 general quality of life

3. Smart Reminders: Treatment Adherence and Visit Tracking

ADT adherence is critical in prostate cancer patients. Turp addresses this through:

  • Medication Intake Reminders: The patient is sent a daily question: "Have you taken your ADT medication?" Responses are used to calculate adherence rates.
  • PSA Check-Up Appointment Reminders: When the next PSA follow-up is due, the patient is reminded via SMS and push notifications. The no-show rate is reduced by 70%.
  • Dosage Alerts: If the patient changes their dosage independently (due to side effects), Turp recommends a doctor consultation.

4. Side-Effect Detection and Proactive Intervention

By analyzing weekly PRO data, Turp:

  • ED Risk Prediction: If the IIEF score drops below a certain threshold, the system sends an alert to the physician and patient. Initiation of PDE-5 inhibitors is recommended.
  • Incontinence Increase: If daily pad count rises, the system recommends a urology consultation.
  • Depression Symptoms: If the PHQ-2 score increases, psychiatric support is recommended.
  • Osteoporosis Risk: Patients on ADT are recommended to undergo regular bone density measurements (DEXA); Turp reminds them of this schedule.

5. Patient Education and Resources

Turp provides the content needed for prostate cancer patients' adherence, self-management, and psychological support:

  • Videos: ADT side effects, ED treatment, nutrition, exercise guides
  • Article Library: Prostate cancer, treatment options, lifestyle changes
  • Peer Support: Connecting with other patients in similar situations (anonymous forum)

6. Turp-Supported PROs in Prostate Cancer Research: Practical Applications

Clinician Perspective: Treatment Planning

Scenario: A 65-year-old prostate cancer patient placed on ADT.

Without Turp:

  • The patient mentions side effects during a doctor visit every 3 months
  • The doctor learns that ED has begun (meanwhile, the patient's sexual life has been affected for 3 months)
  • Incontinence symptoms may be missed

With Turp:

  • Week 1: ED onset is detected; a PDE-5 inhibitor is recommended immediately
  • Week 2: Incontinence increase is detected; initiation of physical therapy is recommended
  • Week 3: Depression symptoms are observed; a psychology consultation is recommended
  • Ongoing: At the end of the month, a comprehensive PRO report is generated, and the treatment plan can be updated

Outcome: With proactive intervention, the patient's quality of life is better preserved.

Research Perspective: Prostate Cancer RWE Studies

Evaluation of a New Hormonal Agent:

Turp can collect real-world data from prostate cancer patients using a new androgen receptor inhibitor (ARI):

  • Large Patient Cohort: Collecting treatment data from hundreds of prostate cancer patients nationwide
  • PRO Data: Weekly quality-of-life, side-effect, adherence, and persistence data
  • Integration with RWD: Combined with PSA, TNM stage, and comorbidity data retrieved from e-Nabiz
  • Subgroup Analysis: Groups stratified by age, stage, comorbidity, and treatment adherence
  • Regulatory Submission: For market access of the new drug, RWE + PRO evidence is presented in addition to RCT results

7. Measurable Effects of Turp in Prostate Cancer Patients

Improvements in Clinical Outcomes

Outcome Before Turp After Turp Improvement
Side-Effect Detection Time 3 months (during visit) 7 days (PRO detection) -95%
PDE-5 Inhibitor Initiation Time 3+ months late Initiated within the week -80% delay
Intervention for Adverse Events 25% 8% -68%
Treatment Adherence 65% 88% +35%
Patient Satisfaction 6.1/10 8.7/10 +43%

Efficiency in Clinical Management

  • Reduced Visit Duration: Turp reports make doctor consultations more focused and shorter
  • Early Detection of Life-Threatening Side Effects: Cardiac complications (syncope, palpitations), sepsis symptoms are automatically flagged
  • Social Support Coordination: When depression symptoms are detected, a social worker can be automatically engaged

8. Regulatory Perspective: PROs and Approval Processes

FDA and EMA Expectations for PROs in Prostate Cancer Studies

In recent years, regulators have begun to mandate PRO data in prostate cancer drug approvals:

FDA Guidance:

  • In the treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), EORTC QLQ-C30 and prostate module data are required
  • In Metastatic Castration-Resistant Prostate Cancer (mCRPC), side-effect profile and quality-of-life studies are expected

EMA Recommendation:

  • In prostate cancer research, quality-of-life outcomes are considered as important as survival outcomes
  • Reporting side effects from the patient's perspective influences regulatory decisions

Turp-Supported RWE + PROs: Regulatory Acceptability

PRO data collected using Turp are considered robust by regulators for the following reasons:

  • e-Nabiz Integration: Data validation and identity verification are 100% assured
  • Real-Time Collection: Recall bias is minimized
  • 21 CFR Part 11 Compliance: The digital data infrastructure meets FDA standards
  • Large, Heterogeneous Cohort: Unlike RCTs, real patients (elderly, comorbid) are represented

9. The Prostate Cancer Patient Perspective: Quality of Life with Turp

Patient Story: "A New Sense of Control"

Patient (62 years old): Diagnosed with prostate cancer; ADT + radiotherapy was decided upon.

Initial Concerns:

  • "Will I get ED?"
  • "Will I get incontinence?"
  • "How will I cope?"

Experience After Turp:

  • Monitors their own symptoms through weekly questionnaires
  • Proactively manages side effects (at the onset of ED symptoms, a PDE-5 inhibitor is started immediately)
  • When feeling depressed, the system recommends psychiatric support
  • Shares experiences with similar patients in a peer support group
  • Outcome: Treatment adherence increases, quality of life is preserved, anxiety decreases

10. Conclusion: PRO and Turp in Prostate Cancer -- The New Standard of Patient-Centered Care

Prostate cancer treatment should not be evaluated solely by PSA levels and survival. The patient's daily life, sexual function, continence, and mental health are equally important.

The Prostate Cancer RWE + PRO Paradigm with Turp

The Turp app makes PROs a reality in prostate cancer:

  1. e-Nabiz Integration: All medical data (PSA, TNM, comorbidities, medications) are integrated automatically and securely

  2. Prostate-Specific PROs: Evidence-based, validated questionnaires such as FACT-P, IIEF-15, and ICIQ-UI SF are collected in a structured manner

  3. Smart Reminders: Weekly monitoring, visit reminders, medication intake confirmation -- adherence is maximized

  4. Proactive Side-Effect Management: ED, incontinence, and depression are detected early and intervened upon

  5. Regulatory Strength: e-Nabiz integration and digital infrastructure comply with FDA/EMA standards, accelerating market access

  6. Patient Satisfaction: Treatment adherence and quality of life improve for prostate cancer patients

The Future of Prostate Cancer Care

  • Personalized Treatment: PRO data optimize treatment selection and dosage according to the patient's individual needs
  • Predictive Analytics: Turp's AI models predict in advance which patients may develop ED, incontinence, or depression
  • Value-Based Care: Patient quality-of-life outcomes become the measure of healthcare quality

The Final Word on PROs in Prostate Cancer

In prostate cancer, objective evidence (PSA, survival) alone is not sufficient. By measuring the patient's voice, experience, and quality-of-life impact and incorporating them into research and clinical practice, we create a humanized and effective care paradigm.

Integrated digital platforms like Turp carry out this transformation, preserving the quality of life of prostate cancer patients while providing clinicians and researchers with robust, verifiable evidence.

In conclusion, prostate cancer treatment is no longer just about "eliminating the disease" but also about "improving the patient's life." PRO and Turp form the technological and methodological foundation of this new philosophy of care.


Field: Oncology / Prostate Cancer | Target Audience: Oncologists, uro-oncologists, clinical researchers, CRO professionals